4 recruiting, 3 unknown, 2 completed, 2 terminated. 13 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 4, Unknown 3, Completed 2, Terminated 2, Not yet recruiting 1, Suspended 1 |
| Phase 1 | 4 | Completed 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC). RAG-01, Chemotherapy agent - Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Not yet recruiting | Ractigen Therapeutics. | 114 | 2026-09-01 | 2026-09-15 |
| Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Low Dose Radiotherapy Combined with Tislelizumab and Chemotherapy, Chemotherapeutic Agent, low-dose radiotherapy - Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Jiangsu Cancer Institute & Hospital | 114 | 2026-05-14 | 2026-11-06 |
| Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial Sintilimab, Chemotherapy Drugs, radiotherapy - Rectal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 130 | 2026-05-01 | 2026-05-19 |
| Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC Carrelizumab, Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), Carboplatin - Non Small Cell Lung Cancer | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 30 | 2021-08-20 | 2021-09-02 |
| Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs - Ovarian Carcinosarcoma, Endometrial Carcinosarcoma | Phase 2 / Phase 3 | Recruiting | ARCAGY/ GINECO GROUP | 138 | 2020-07-15 | 2026-09-09 |
| A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients Plasma soluble TNF receptor pulldown, Plasma soluble TNF receptor pulldown + chemotherapy, Chemotherapy Drugs, Cancer - Advanced Breast Cancer | Phase 1 / Phase 2 | Unknown | Immunicom Inc | 170 | 2019-05-31 | 2022-03-24 |
| Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer Chemotherapy Drugs, Cancer - Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Shaare Zedek Medical Center | 15 | 2019-04-18 | 2020-10-23 |
| Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer Bevacizumab - Advanced Ovarian Cancer | Phase 2 | Unknown | Nada Hassan Salah | 40 | 2018-09-01 | 2018-08-02 |
| Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients Oshadi D & Oshadi R;, salvage therapy cytosar and mitoxantrone - Acute Myeloid Leukemia, Lymphoid Leukemia | Phase 2 | Suspended | Oshadi Drug Administration | 15 | 2017-01-01 | 2018-04-18 |
| Chemoembolization for Hepatocellular Carcinoma TACE, Cisplatin - Hepatocellular Carcinoma | Phase 2 | Terminated | Chinese University of Hong Kong | 24 | 2012-02-01 | 2017-08-22 |
| Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) Idarubicin, Cytarabine, Lenalidomide (Revlimid®) - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 51 | 2009-06-25 | 2020-12-22 |
| To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid Paclitaxel, Drug: Ad.p53-DC vaccines, All -trans Retinoic Acid (ATRA) - Small Cell Lung Cancer | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 69 | 2007-10-02 | 2019-11-08 |
| ABT-751 With Chemotherapy for Relapsed Pediatric ALL ABT-751, Dexamethasone, PEG-asparaginase - Recurrent Pediatric ALL, Relapsed Pediatric ALL | Phase 1 / Phase 2 | Terminated | Therapeutic Advances in Childhood Leukemia Consortium | 9 | 2006-05-22 | 2021-03-17 |
Breast Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, Lymphoid (1) · Leukemia, Monocytic, Acute (1) · Myelodysplastic Syndromes (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Rectal Neoplasms (1) · Recurrence (1) · Small Cell Lung Carcinoma (1)
H. Lee Moffitt Cancer Center and Research Institute (2) · ARCAGY/ GINECO GROUP (1) · Chinese University of Hong Kong (1) · Immunicom Inc (1) · Jiangsu Cancer Institute & Hospital (1) · Nada Hassan Salah (1) · Oshadi Drug Administration (1) · Ractigen Therapeutics. (1) · Shaare Zedek Medical Center (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (4) · United States (3) · France (1) · Hong Kong (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1) · Turkey (Türkiye) (1)
Adam Ostrowski, MD (1) · Alberto A Gabizon, MD, PhD (1) · Dingwei Ye (1) · Gang Li, PhD. MD. (1) · Jeffrey Lancet, M.D. (1) · Moshe Gatt, MD (1) · Paul S Gaynon, MD (1) · Scott Antonia, M.D. (1) · Simon Yu (1) · Yongde Liao, PhD (1)
PMID 14998846, PMID 25415656, PMID 26408258, PMID 27912846, PMID 42361329